Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
Launched by PSYRIN INC. · Jan 19, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. Participants aged between 16 and 60 years.
- • 2. Individuals currently undergoing or referred for clinical assessment of mental or behavioral health conditions (including but not limited to ADHD, ASD, BPAD, GAD, MDD, OCD, PTSD, SSD)
- • 3. Fluent in English
- • 4. Capable of providing informed consent, or in the case of minors, having a parent or legal guardian who can provide consent on their behalf.
- • 5. Access to a device (smartphone, tablet, or computer) with a microphone and stable internet connectivity, necessary for completing the speech tasks.
- • Exclusion Criteria
- • 1. Individuals experiencing acute mental health crises or severe symptoms that would preclude meaningful participation in the study, including acute intoxication.
- • 2. Severe cognitive impairment or intellectual disability that would prevent understanding of the study procedures or completion of the speech tasks.
- • 3. Lack of fluency in English.
- • 4. Technical limitations: Inability to access a suitable device or internet connection for completing the speech tasks
About Psyrin Inc.
Psyrin Inc. is an innovative clinical trial sponsor dedicated to advancing mental health therapies through rigorous scientific research and development. With a focus on neuropsychiatric disorders, Psyrin leverages cutting-edge methodologies and a patient-centered approach to deliver impactful solutions. The company collaborates with leading academic institutions and healthcare professionals to design and execute clinical trials that prioritize safety, efficacy, and ethical standards. Committed to transforming the landscape of mental health treatment, Psyrin Inc. strives to bring novel therapies from the laboratory to the clinic, ultimately improving patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brookline, Massachusetts, United States
Zanesville, Ohio, United States
Patients applied
Trial Officials
Julianna Olah, B.Sc., M.A., M.Sc., Ph.D.
Principal Investigator
Psyrin Inc.
Atta-ul Raheem R Chaudhry, B.Sc. (Hons.), M.B.B.S.
Principal Investigator
Psyrin Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported